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Purpose: Clinical outcomes of papillary thyroid microcarcinoma (PTMC) vary. In general, age at diagnosis is an independent 
prognostic factor in conventional papillary thyroid carcinoma. However, it is unclear in patients of PTMC. The purpose of 
this study was to identify clinicopathologic features and prognostic factors of PTMC according to patients’ age. Methods: 
Five hundred twenty-seven patients who received thyroid surgery and diagnosed as having PTC between January 2001 and 
December 2009 were included. The clinical data were retrospectively analyzed. Results: We divided the patients into two 
groups; group I who were younger than 45 years, and group II who were 45 years old or older. The mean tumor size and in-
cidences of neck lymph nodes involvement of group I was larger than group II. In group II, however, there were more pa-
tients who had multiple cancer foci and were body mass index ≥  25 kg/m
2. The overall incidence of recurrent disease was 
3.2%. The incidence of recurrence was higher in group II (2.0% vs. 4.0%), without a statistical difference. In multivariate anal-
ysis, the significant risk factors of recurrence were male gender and multifocality in group I, and lymph node metastasis and 
multifocality in group II. In particular, the male gender and multifocality showed the highest odds ratio (OR) on each group 
(OR, 4.721 and 6.177). Conclusion: The patients with PTMCs had different clinical features and prognostic factors according 
to age. Hence, clinicians should consider a different strategy for therapy and plan for follow-up according to age. 
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INTRODUCTION
Papillary thyroid microcarcinoma (PTMC) is defined as 
a papillary thyroid cancer measuring 10 mm or less in 
maximum diameter [1]. Advances in ultrasonography- 
guided fine needle aspiration cytology have resulted in a 
marked increase in the number of patients diagnosed with 
PTMC [2].
Clinical outcomes of PTMC vary. Most PTMCs have an 
indolent course and excellent prognosis [3-6]. However, 
some PTMCs result in recurrence, distant metastasis, or 
mortality [3,7,8]. Therefore, the optimal management of 
PTMC remains controversial, ranging from conservative 
treatment to more aggressive treatment as with other ma-
lignancies of the thyroid [2,3,6,9-12]. To date, there are no 
confirmative factors to predict the prognosis of PTMCs, al-
though the BRAF
V600E mutation with aspiration specimen 
is associated with poor prognostic factors such as lymph Jin-Kyu Cho, et al.
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node metastasis, tumor size, extrathyroid extension and 
multifocality [13-18].
In general, age at diagnosis is an independent prog-
nostic factor in conventional papillary thyroid carcinoma 
(PTC). Older patients tend to have more locally aggressive 
tumors and a higher incidence of distant metastases at di-
agnosis and more aggressive histologic variant, factors 
that locally portend a more dismal outlook. However, it is 
unclear whether these findings hold among patients of 
PTMC. We therefore examined the clinicopathologic fea-
tures and prognostic factors of PTMC according to patient 
age.
METHODS
We reviewed the charts of the patients who underwent 
thyroid surgery for malignancy from January 2001 to 
December 2009 in Gyeongsang National University 
Hospital. Among these, patients who were diagnosed 
with PTMC after operation were selected for this study. 
And the patients with other malignancies or history of pre-
vious thyroidectomy were excluded from the study. 
Of the 1,145 patients with PTC, 539 patients were diag-
nosed as having PTMC. Of these patients, 12 patients were 
excluded because 8 patients were diagnosed with other 
malignancies before or after operation, and 4 patients 
were already had hemi-thyroidectomies due to benign 
disease of the thyroid. Thus, the remaining 527 patients 
were included in this study.  
The epidemiologic factors and pathologic reports after 
operation were examined based on chart review. For each 
patient, height and weight was used to calculate body 
mass index (BMI) according to its determined formula 
(i.e., BMI = weight, kg / [height, m]
2).
In our institution, methods of operation were selected 
by tumor characteristics. If the patients had no bilateral tu-
mor foci, lymph node metastasis and grossly soft tissue in-
vasion, we would perform a hemi-thyroidectomy as an in-
itial operation. If lymph node metastasis was observed af-
ter the hemithyroidectomy, completion thyroidectomy 
was recommended, and these patients were considered to 
have undergone total thyroidectomy in the analysis. But 
the five patients who were recommended to undergo com-
pletion thyroidectomy were followed up without receiv-
ing it. After surgery, most patients received thyroid hor-
mone suppressive therapy for at least 6 months. Among 
the patients who had neck lymph node metastasis or three 
or more multiple cancer foci after receiving total thyroi-
dectomy, post-operative radio-active iodine (RAI) therapy 
was performed. But, the patients who refused to undergo 
RAI due to such reasons as their general condition, even 
though they met the criteria and were recommended to 
undergo treatment, were also included in the analysis.
Postoperative investigation usually consisted of thy-
roid ultrasonography, thyroid function test, and/or 
131I 
whole-body diagnostic scanning. Postoperative inves-
tigation was performed 6 months after surgery and at 6 to 
12-month intervals thereafter. 
Chi-square test and Fisher’s exact test were used to ana-
lyze the significance of difference in the clinical features. 
Logistic regression analysis was performed for multi-
variate analysis to determine significant factors associated 
with recurrence among the age’s group. In addition, sur-
vival rates were calculated by the Kaplan-Meier method 
and were compared by the log-rank test. All statistical 
analyses were performed using SPSS ver. 15.0 (SPSS Inc., 
Chicago, IL, USA) and P-value ＜ 0.05 were considered 
statistically significant. 
RESULTS
The mean age of the patients with PTMCs was 47.67 ± 
11.452 years old (range, 15 to 73 years). We divided the pa-
tients with PTMCs into two groups according to age. 
Group I was patients who were younger than 45 years old 
at the time of diagnosis, and group II was patients who 
were 45 years old or older. Two hundred five patients 
(38.9%) belonged to group I and 322 belonged to group II.
Clinicopathologic features 
The clinicopathologic features of patients with PTMC 
according to age group are given in Table 1. 
There was no significant difference of sex in two groups. 
The mean tumor size of PTMCs of group I was larger than Clinical features and prognostic factors in PTMC
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Group I (n = 205) Group II (n = 322) P-value
  Male:female 38:167 51:271 0.474
  Cancer size (cm) 0.71 ± 0.24 0.67 ± 0.24
    ＜0.5     56 (27.3)    116 (36.0) 0.045
    ≥0.5   149 (72.7)    206 (64.0)
  Capsular invasion     72 (35.1)    135 (41.9) 0.121
  Neck LN involvement 45/81 (55.56) 49/128 (38.28) 0.016
    Lateral neck LN involvement 3 2 0.874
  Multiplicity
    Solitary 175 (85.4) 236 (73.3) 0.001
    Multiple   30 (14.6)   86 (26.7)
  Unilateral 16 33 0.002
  Bilateral 14 53
  Operation methods 0.000
    Total thyroidectomy   88 (42.9) 206 (64.0)
    Hemithyroidectomy 117 (57.1) 116 (36.0)
  RAI therapy 14 (6.8)   51 (15.8) 0.003
  BMI (kg/m
2) 0.031
    ＜25 145 (70.7) 198 (61.5)
    ≥25   60 (29.3) 124 (38.5)
  Recurrence   4 (2.0) 13 (4.0) 0.216
Values are presented as mean ± SD or number (%).
Group I, patient’s age ＜  45 years; Group II, patient’s age ≥  45 years.
SD, standard deviation; LN, lymph node; RAI, radio-active iodine; BMI, body mass index.
Table 1. The clinicopathologic features of patients with papillary thyroid microcarcinoma
group II. The incidences of neck lymph nodes involvement 
were higher in group I (22.0% vs. 15.2%, P = 0.033), and the 
patient ratio of BMI ≥  25 kg/m
2 was lower in group I than 
group II (29.3% vs. 38.5%, P = 0.031). In group II, however, 
there were more patients who had multiple cancer foci, es-
pecially in both thyroid lobes. The capsular invasion of 
cancer was also higher in group II, but there was no sig-
nificant difference between the groups.
Total thyroidectomy and radioactive iodine ablation 
treatment were more frequently performed in patients of 
group II (P = 0.000 and 0.003).
Tumor recurrence
The follow-up period ranged from 5.6 to 120.0 months 
and mean period was 48.2 ± 24.6 months. After that period, 
there was no distant metastasis or death related to PTMC. 
The overall incidence of recurrent disease was 3.2%. 
One patient developed a recurrent mass on the remnant 
thyroid after hemithyroidectomy, one had recurrence on 
both the thyroid bed and lateral neck lymph node, and the 
other 15 patients had only lateral neck lymph node 
recurrence. 
The incidence of recurrence was higher in group II (2.0% 
vs. 4.0%), without being statistically difference (P = 0.216).
The interval from initial surgery to recurrence ranged 
from 5.1 to 81.3 months. No difference was identified in 
the interval periods of recurrence among the two groups. 
Risk factors of recurrence 
In group I, male gender, multifocality and BMI were sig-
nificantly associated with recurrence at univariate 
analysis. However, in group II, the capsular invasion, neck 
lymph node metastasis, multifocality at diagnosis and 
RAI treatment after operation were independent risk fac-
tors for recurrence (Table 2).
For each group, a univariate analysis was performed 
and the factors that were deemed meaningful in the analy-
sis were further analyzed through a multivariate analysis. 
At multivariate analysis, the significant risk factors of re-
currence were male gender and mutifocality in group I (P 
= 0.03 and 0.04), and lymph node metastasis and multi-
focality in group II (P = 0.01 and 0.01). In particular, male Jin-Kyu Cho, et al.
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Group I
P-value
Group II
P-value
Non-recur Recur Non-recur Recur
Sex 0.021 0.235
  Male   35 (17.4) 3 (75.0)   51 (16.5) 0 (0)
  Female 116 (82.6) 1 (25.0) 258 (83.5) 13 (100.0)
Cancer size (cm)
  ＜0.5   56 (27.9) 0 (0) 0.577 111 (35.9) 5 (38.5) 1.000
  ≥0.5  145 (72.1)   4 (100.0) 198 (64.1) 8 (61.5)
Capsular invasion   71 (35.3) 1 (25.0) 1.000 126 (40.8) 9 (69.2) 0.049
Neck LN involvement   43 (21.4) 2 (50.0) 0.210   42 (13.6) 7 (53.8) 0.001
Multiplicity 0.044 0.001
  Solitary 173 (86.1) 2 (50.0) 232 (75.1) 4 (30.8)
  Multiple   28 (13.9) 2 (50.0)   77 (24.9) 9 (69.2)
    Unilateral 16 0 0.002 31 2 0.001
    Bilateral 12 2 46 7
Operation methods 1.000 0.557
  Total thyroidectomy   86 (42.8) 2 (50.0) 199 (64.4) 7 (53.8)
  Hemithyroidectomy 115 (57.2) 2 (50.0) 110 (35.6) 6 (46.2)
RAI therapy 14 (7.0) 0 (0) 1.000   46 (14.9) 5 (38.5) 0.039
BMI (kg/m
2) 0.042 0.773
  ＜25 144 (71.6) 1 (25.0) 189 (61.2) 9 (69.2)
  ≥25   57 (28.4) 3 (75.0) 120 (38.8) 4 (30.8)
Values are presented as number (%).
Group I, patient’s age ＜  45 years; Group II, patient’s age ≥  45 years.
SD, standard deviation; LN, lymph node; RAI, radio-active iodine; BMI, body mass index.
Table 2. Risk factors of recurrence of patients with papillary thyroid microcarcinoma according to age group
Group Factor Odds ratio P-value 95% CI
I Sex (male) 4.721 0.030 0.005-0.763
Multiple 4.072 0.044 1.070-106.886
BMI (≥25 kg/m
2) 1.885 0.170 0.485-61.075
II Capsular invasion 1.902 0.168 0.680-9.167
LN metastasis 5.498 0.019 1.322-22.629
Multiple 6.177 0.013 1.397-16.956
RAI therapy 0.089 0.766 0.168-3.714
CI, confidence interval; BMI, body mass index; LN, lymph node; RAI, radio-active iodine.
Table 3. Multivariate analysis of factors affecting the recurrence in each age group of papillary thyroid microcarcinomas
gender and multifocality showed the highest odds ratio 
(OR) in each group (OR, 4.721 and 6.177) (Table 3).
By the Kaplan-Meier survival analysis, recurrence-free 
survival was higher in group I (98.0% vs. 95.9%), but there 
was no significant difference between the groups 
(log-rank = 0.078) (Fig. 1). Of group I, the recurrence-free 
survival of male was lower than female, it was significant 
(M : F = 92.1% : 99.4%; log-rank = 0.010) (Fig. 2A). Also, of 
group II, the recurrence-free survival of the patients with 
solitary PTMCs was higher than the others (solitary : mul-
tiple = 98.3% : 88.9%; log-rank = 0.000) (Fig. 2B).
DISCUSSION
Recently, several papers have focused on the clinical sig-
nificance, the appropriate treatment, and the prognostic 
features of PTMC [6,19,20]. Obviously, the increasing in-
terest in this disease worldwide has resulted in more fre-
quent diagnosis. Grodski and Delbridge [20] have demon-Clinical features and prognostic factors in PTMC
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Fig. 1. Recurrence-free survival rate of papillary thyroid micro-
carcinoma according to age group by the Kaplan-Meier survival 
analysis. The recurrence-free survival was higher in group I, but 
there was no significant difference between the groups.
Fig. 2. Recurrence-free survival rate of papillary thyroid microcarcinoma (PTMC) according to sex in group I patients. (A) Stratified by sex in 
the group I. The recurrence-free survival of male was lower than female (log-rank = 0.010). (B) Stratified by multiplicity in the group II. The 
recurrence-free survival of the patients with solitary PTMCs was higher than the others (log-rank = 0.000).
strated that the incidence of PTC has almost doubled over 
the last three decades, mainly due to the higher incidence 
of PTMC.  
According to the seventh edition of tumor, node, meta-
stasis system classification by the American Joint 
Committee on Cancer, age is an important prognostic fac-
tor [21]. Of the PTMCs, if the patient’ age is younger than 
45 years old; the stage is just I regardless of extrathyroid 
extension and lymph node metastasis. If the patient’s age 
is 45 years old or older, their stages might be upgraded ac-
cording to tumor characteristics. Recently, Yu et al. [22] re-
ported that an age greater than 45 years was poor survival 
factor in PTMC, so they stated that older patients should 
be considered for more aggressive treatment. However, 
other studies reported that age was not a prognostic factor 
of PTMC. Similarly, in this study, the recurrence rate was 
higher in older group, but there was also no significant dif-
ference between the groups. Therefore, we sought to ex-
amine the clinical impact according to age rather than age 
as prognostic factor. 
According to studies, the recurrence rate of PTMC rang-
es from 3 to 16.7%, and they reported the prognostic fac-
tors; tumor size, postoperative Tg level, presence of lymph 
node metastases at diagnosis, sex, and extent of surgery 
[3,10,11,14,17,18]. The lateral neck lymph node metastases 
have been considered a confirmative prognostic factor of 
PTMC, but there is considerable debate concerning central 
neck lymph node metastases [14,15]. Also, routine pro-
phylactic central neck lymph node dissection for PTMC 
has been debated because prophylactic node dissection 
seems to have little prognostic benefit [6,23,24]. So et al. 
[25] reported that the lymph node metastasis was not asso-
ciated with age, but Lombardi et al. [17] reported that the 
patients who had lymph node metastasis were younger 
than others. In our study, the incidence of lateral neck 
lymph node metastases at the time of diagnosis was too 
low at 0.9%, so it might be difficult to analyze the sig-
nificance of lateral lymph nodes on PTMC. Of all, the in-
cidence of neck lymph node metastases was higher in pa-
tients whose age was less than 45 years. Patients with 
lymph node metastases showed higher recurrence rates Jin-Kyu Cho, et al.
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than patients without them. However, lymph node meta-
stases revealed significant prognostic factors for re-
currence in only the patients whose ages were 45 years or 
older. 
Multifocal lesions in PTMC are not an unusual finding 
like conventional PTC. In general, the incidence of multi-
focality has been reported to be 19 to 32%. In our study, 
22% of the PTMC patients had multifocal cancers and 
57.8% of them had bilateral cancer. Multifocality was the 
only significant prognostic factor on both age groups (OR: 
group I, -4.072 and group II, -6.177; P-value ＜ 0.05). 
Therefore, the multifocality of PTMC was considered to be 
one of the most significant prognostic factors regardless of 
age.
The association with sex and prognosis of PTMC has 
been debated. Recently, Roh et al. [26] reported that there 
was no association between sex and lymph node 
metastasis. Unexpectedly, Besic et al. [27], and So et al. [25] 
reported that the male gender had a tendency toward 
node metastasis. However, there was little evidence for the 
relationship between sex and the recurrence or survival in 
patients with PTMC. In this study, of the patients aged less 
than 45 years, males were revealed to be a significant factor 
affecting to recurrence, and the OR was 4.721 on multi-
variate analysis. 
Positive associations between BMI and thyroid cancer 
have been reported in large prospective studies and 
meta-analysis [28-30], but there has been no evidence 
whether these findings hold among patients of PTMC. In 
our study, the patients with a BMI of ≥25 kg/m
2 showed 
the tendency to have poor prognosis in univariate analysis 
but not in multivariate analysis. Further studies on this is-
sue are needed. 
Our study had some limitations. The first limitation of 
this study is the fact that it was a retrospective study with 
patients from a single institution. The second limitation is 
that this study resulted from short periods of follow-up 
(mean, 48.2 ± 24.6 months). So, if we follow-up over long 
periods, we may have a higher recurrence rate than now 
along with different prognostic factors. Hence, we think 
that it is necessary to perform a prospective study on dis-
ease recurrence and survival for the two groups with 
long-term follow-up periods. 
In this study, we found that although age itself was not 
independent prognostic factor of recurrence in PTMC, the 
different age groups had different clinical features and 
prognostic factors. Sex and multifocality of cancer were 
the significant factors determining recurrence in patients 
aged ＜45; and the lymph node metastases and multi-
focality in patients aged ≥45 years old. Therefore clini-
cians should consider a different strategy of therapy and 
plan for follow-up according to age. 
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